Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Alisertib response rate in PTCL patients was 33%

Key clinical point: Despite failing to best current chemotherapies for relapsed/refractory peripheral T-cell lymphoma, a new report suggests that alisertib might have a role as a last-ditch option.

Major finding: Overall response rate (ORR) was 33% for alisertib versus 45% for the comparator arm (odds ratio, 0.60; 95% confidence interval, 0.33-1.08).

Study details: Open-label trial in 271 relapsed/refractory PTCL patients.

Disclosures: The work was funded by alisertib maker Millennium Pharmaceuticals, a subsidiary of Takeda. Investigators reported various ties to Millennium and Takeda, including research funding, honoraria, and consulting work. The study team included employees of those companies.